TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study of a Mobile Health Approach to Reduce Barriers to Cervical Cancer Screening in Tanzania
Brief Summary: The purpose of this study is to determine whether motivational text messages and/or travel vouchers are effective in increasing cervical cancer screening rates in urban and rural regions of Northern Tanzania.


Options:
A: Arm Label: Standard of Care (SoC); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SoC + iTab; Type: ACTIVE_COMPARATOR; Interventions: Device: SoC + iTab | Intervention Type: DEVICE; Name: SoC + iTab; Assigned to Arm(s): SoC + iTab
B: Arm Label: Kilkari; Type: EXPERIMENTAL; Interventions: Other: Kilkari | Arm Label: Comparison; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Kilkari; Assigned to Arm(s): Kilkari
C: Arm Label: Multilevel Gaming Adherence; Type: EXPERIMENTAL; Interventions: Behavioral: Multilevel Gaming Adherence Intervention | Arm Label: Treatment as Usual +; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as Usual + | Intervention Type: BEHAVIORAL; Name: Multilevel Gaming Adherence Intervention; Assigned to Arm(s): Multilevel Gaming Adherence | Intervention Type: BEHAVIORAL; Name: Treatment as Usual +; Assigned to Arm(s): Treatment as Usual +
D: Arm Label: Motivational SMS; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational SMS | Arm Label: Travel Voucher; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational SMS, Behavioral: Travel Voucher | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational SMS; Assigned to Arm(s): Motivational SMS, Travel Voucher | Intervention Type: BEHAVIORAL; Name: Travel Voucher; Assigned to Arm(s): Travel Voucher

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Robot Assisted Gait Training in Patients With Infratentorial Stroke
Brief Summary: The Effect of Robot Assisted Gait Training in Patients With Infratentorial Stroke


Options:
A: Arm Label: Exoskeleton Program; Type: EXPERIMENTAL; Interventions: Device: Exoskeleton Program | Arm Label: Usual Care Program; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care Program | Intervention Type: DEVICE; Name: Exoskeleton Program; Assigned to Arm(s): Exoskeleton Program | Intervention Type: OTHER; Name: Usual Care Program; Assigned to Arm(s): Usual Care Program
B: Arm Label: Stride Management Assist (SMA) System; Type: EXPERIMENTAL; Interventions: Device: The Stride Management Assist (SMA) System | Arm Label: Impairment based therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Impairment based therapy | Intervention Type: DEVICE; Name: The Stride Management Assist (SMA) System; Assigned to Arm(s): Stride Management Assist (SMA) System | Intervention Type: OTHER; Name: Impairment based therapy; Assigned to Arm(s): Impairment based therapy
C: Arm Label: Robot, then conventional training; Type: EXPERIMENTAL; Interventions: Other: Robot, then conventional training | Arm Label: Conventional, then robot training; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional, then robot training | Intervention Type: OTHER; Name: Robot, then conventional training; Assigned to Arm(s): Robot, then conventional training | Intervention Type: OTHER; Name: Conventional, then robot training; Assigned to Arm(s): Conventional, then robot training
D: Arm Label: Ankle Robot with Power Assistance; Type: EXPERIMENTAL; Interventions: Device: Ankle Robot with Power Assistance | Arm Label: Sham group; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham | Intervention Type: DEVICE; Name: Ankle Robot with Power Assistance; Assigned to Arm(s): Ankle Robot with Power Assistance | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Obstetric Perineal Trauma, Pelvic Floor Symptoms and Early Physiotherapy Intervention
Brief Summary: The main objective is to investigate effects of perineal trauma at birth on women´s health and whether early physiotherapy improves pelvic floor strength. This will be achieved by an acknowledged/validated questionnaire sent electronically 6 weeks after first delivery. Women with symptomes of urinary incontinence according to the questionnaire will be offered participation in a single-blinded randomized intervention study to compare outcome after targeted physiotherapy with conventional advice and support. Intervention encompasses weekly pelvic floor training for 12 weeks. Pelvic strength will be measured and symptom information collected before and after intervention and 12 months postpartum in both groups.

Pelvic floor problems after delivery are common and often persistent, including urinary/fecal incontinence, pelvic organ prolapse and sexual problems. Such symptoms reduce QoL and handicap women in multiple ways, physically, psychologically and socially. More knowledge of whether interventions and guidelines in this field can improve health and QoL is required.


Options:
A: Arm Label: Lifestyle & Behavioral Change Program; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle & Behavioral Change Program | Arm Label: Structured Education Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured Education Program | Intervention Type: BEHAVIORAL; Name: Lifestyle & Behavioral Change Program; Assigned to Arm(s): Lifestyle & Behavioral Change Program | Intervention Type: BEHAVIORAL; Name: Structured Education Program; Assigned to Arm(s): Structured Education Program
B: Arm Label: Physiotherapy intervention; Type: EXPERIMENTAL; Interventions: Other: Physiotherapy intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Physiotherapy intervention; Assigned to Arm(s): Physiotherapy intervention
C: Intervention Type: BEHAVIORAL; Name: Supervised exercise for the prevention high weight gain; Assigned to Arm(s): N/A
D: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured training and leaflet | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured training | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Leaflet | Arm Label: Group 4; Type: SHAM_COMPARATOR; Interventions: Behavioral: Control Group | Intervention Type: BEHAVIORAL; Name: Structured training and leaflet; Assigned to Arm(s): Group 1 | Intervention Type: BEHAVIORAL; Name: Structured training; Assigned to Arm(s): Group 2 | Intervention Type: BEHAVIORAL; Name: Leaflet; Assigned to Arm(s): Group 3 | Intervention Type: BEHAVIORAL; Name: Control Group; Assigned to Arm(s): Group 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Establishing the Effect(s) and Safety of Fluoxetine Initiated in the Acute Phase of Stroke
Brief Summary: The purpose of this study is to investigate whether routine administration of fluoxetine 20mg once daily in the 6 months initiated during the acute stroke improves the patient's functional outcome.

EFFECTS is an investigator lead Sweden-based, multicenter, parallel group, double blind placebo controlled trial with broad entry criteria and follow up at 6 and 12 months.

EFFECTS managed to recruit its anticipated numbers of 1,500 participants between 20th October 2014 and 28th June 2019. Data will be unblinded when the 6-months follow-up is completed, and the primary outcome is due to report on May 2020.


Options:
A: Arm Label: Fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Recovering Together; Type: EXPERIMENTAL; Interventions: Behavioral: Recovering Together | Arm Label: Health Education; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Recovering Together; Assigned to Arm(s): Recovering Together
C: Arm Label: In-person behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Brief pleasurable events/behavioral therapy | Arm Label: Telephone behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Brief pleasurable events/behavioral therapy | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: BEHAVIORAL; Name: Brief pleasurable events/behavioral therapy; Assigned to Arm(s): In-person behavioral intervention, Telephone behavioral intervention | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care
D: Arm Label: Dialogue-based psychosocial intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dialogue-based psychosocial rehabilitation | Arm Label: Usual care Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dialogue-based psychosocial rehabilitation; Assigned to Arm(s): Dialogue-based psychosocial intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Establishing the Effect(s) and Safety of Fluoxetine Initiated in the Acute Phase of Stroke
Brief Summary: The purpose of this study is to investigate whether routine administration of fluoxetine 20mg once daily in the 6 months initiated during the acute stroke improves the patient's functional outcome.

EFFECTS is an investigator lead Sweden-based, multicenter, parallel group, double blind placebo controlled trial with broad entry criteria and follow up at 6 and 12 months.

EFFECTS managed to recruit its anticipated numbers of 1,500 participants between 20th October 2014 and 28th June 2019. Data will be unblinded when the 6-months follow-up is completed, and the primary outcome is due to report on May 2020.


Options:
A: Arm Label: Active rTMS/active fluoxetine; Type: EXPERIMENTAL; Interventions: Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS), Drug: Fluoxetine | Arm Label: Sham rTMS/active fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Device: Sham repetitive transcranial magnetic stimulation (rTMS) | Arm Label: Sham rTMS/placebo fluoxetine; Type: EXPERIMENTAL; Interventions: Device: Sham repetitive transcranial magnetic stimulation (rTMS), Drug: Placebo Fluoxetine | Intervention Type: DEVICE; Name: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Assigned to Arm(s): Active rTMS/active fluoxetine | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Active rTMS/active fluoxetine, Sham rTMS/active fluoxetine | Intervention Type: DEVICE; Name: Sham repetitive transcranial magnetic stimulation (rTMS); Assigned to Arm(s): Sham rTMS/active fluoxetine, Sham rTMS/placebo fluoxetine | Intervention Type: DRUG; Name: Placebo Fluoxetine; Assigned to Arm(s): Sham rTMS/placebo fluoxetine
B: Arm Label: SSRI; Type: EXPERIMENTAL; Interventions: Drug: SSRI | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SSRI; Assigned to Arm(s): SSRI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: sugar pill | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): escitalopram | Intervention Type: DRUG; Name: sugar pill; Assigned to Arm(s): placebo
D: Arm Label: Fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Evaluation of the Astral VAPS AutoEPAP Treatment Algorithm
Brief Summary: Patients with chronic respiratory failure such as those associated with Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS), Obstructive Sleep Apnea (OSA) or Neuromuscular Disease (NMD) are increasingly managed with domiciliary non-invasive positive pressure ventilation (NIPPV). The aim of this study is to now compare the Automatic Expiratory Positive Airway Pressure (AutoEPAP) algorithm with a fixed manual EPAP in iVAPS mode on an Astral mixed mode ventilator. It is proposed that the automatic settings of AutoEPAP will be as effective at managing respiratory failure and upper airway obstruction (UAO) as manual EPAP on the Astral device. Specifically demonstrating that the AutoEPAP function is as effective at treating UAO as manual EPAP.


Options:
A: Arm Label: Tiotropium Respimat 5mcg (Tio R5); Type: OTHER; Interventions: Drug: Tiotropium Inhalation Solution | Arm Label: Tiotropium Respimat 10mcg (Tio R10); Type: OTHER; Interventions: Drug: Tiotropium Inhalation Solution | Arm Label: Placebo; Type: OTHER; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Tiotropium Inhalation Solution; Assigned to Arm(s): Tiotropium Respimat 10mcg (Tio R10), Tiotropium Respimat 5mcg (Tio R5) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Observational; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Interventional; Type: EXPERIMENTAL; Interventions: Device: CHROMED monitoring system | Intervention Type: DEVICE; Name: CHROMED monitoring system; Assigned to Arm(s): Interventional
C: Arm Label: iVAPS with AutoEPAP; Type: EXPERIMENTAL; Interventions: Device: Astral | Arm Label: iVAPS with manual EPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: Astral | Intervention Type: DEVICE; Name: Astral; Assigned to Arm(s): iVAPS with AutoEPAP, iVAPS with manual EPAP
D: Arm Label: Lifestyle counselling; Type: EXPERIMENTAL; Interventions: Other: Disease management program | Arm Label: Comparator; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: OTHER; Name: Disease management program; Assigned to Arm(s): Lifestyle counselling | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Comparator

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA(REGISTERED)) VERSUS SUNITINIB (SUTENT(REGISTERED)) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
Brief Summary: This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma


Options:
A: Arm Label: Nivolumab (A); Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: TKI (B); Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib, Drug: Pazopanib | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab (A) | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): TKI (B) | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): TKI (B)
B: Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: IMA901 plus GM-CSF added to sunitinib after single dose of cy; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib, Biological: GM-CSF, Drug: Cyclophosphamide, Drug: IMA901 | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy, Sunitinib | Intervention Type: BIOLOGICAL; Name: GM-CSF; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy | Intervention Type: DRUG; Name: IMA901; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy
C: Arm Label: Avelumab in combination with axitinib; Type: EXPERIMENTAL; Interventions: Drug: Avelumab (MSB0010718C), Drug: Axitinib (AG-013736) | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Avelumab (MSB0010718C); Assigned to Arm(s): Avelumab in combination with axitinib | Intervention Type: DRUG; Name: Axitinib (AG-013736); Assigned to Arm(s): Avelumab in combination with axitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
D: Arm Label: LY2510924 + Sunitinib; Type: EXPERIMENTAL; Interventions: Drug: LY2510924, Drug: Sunitinib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: LY2510924; Assigned to Arm(s): LY2510924 + Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): LY2510924 + Sunitinib, Sunitinib

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Brief Summary: This is a randomized double blind, double dummy, placebo and active comparator controlled, parallel design study that is being performed to assess the safety and efficacy of risankizumab (BI 655066) to support registration for the treatment of moderate to severe chronic plaque psoriasis in adult patients.


Options:
A: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: placebo for ustekinumab | Arm Label: Ustekinumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab, Drug: placebo for risankizumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for ustekinumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Ustekinumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Ustekinumab (Part A) | Intervention Type: DRUG; Name: placebo for ustekinumab; Assigned to Arm(s): Placebo (Part A), Risankizumab (Part A)
B: Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Narrow-band ultraviolet B (nb-UVB); Type: ACTIVE_COMPARATOR; Interventions: Radiation: nb-UVB | Intervention Type: BIOLOGICAL; Name: Secukinumab; Assigned to Arm(s): Secukinumab 300 mg | Intervention Type: RADIATION; Name: nb-UVB; Assigned to Arm(s): Narrow-band ultraviolet B (nb-UVB)
C: Arm Label: adalimumab + placebo; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo (vehicle ointment) | Arm Label: adalimumab + calcipotriol/betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: Calcipotriol/Betamethasone Ointment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone, adalimumab + placebo | Intervention Type: DRUG; Name: Calcipotriol/Betamethasone Ointment; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone | Intervention Type: DRUG; Name: placebo (vehicle ointment); Assigned to Arm(s): adalimumab + placebo
D: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BI 655066/ABBV-066 (Risankizumab) Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis (UltIMMa-1)
Brief Summary: The purpose of this study is to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) for the treatment of moderate to severe chronic plaque psoriasis in adult patients.


Options:
A: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Non-systemic treatment.; Type: ACTIVE_COMPARATOR; Interventions: Device: UVB Phototherapy, Other: Topical treatment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab | Intervention Type: DEVICE; Name: UVB Phototherapy; Assigned to Arm(s): Non-systemic treatment. | Intervention Type: OTHER; Name: Topical treatment; Assigned to Arm(s): Non-systemic treatment.
B: Arm Label: BMS-986165 Dose 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 2; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 3; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 4; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 5; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for BMS-986165 | Intervention Type: DRUG; Name: BMS-986165; Assigned to Arm(s): BMS-986165 Dose 1, BMS-986165 Dose 2, BMS-986165 Dose 3, BMS-986165 Dose 4, BMS-986165 Dose 5 | Intervention Type: DRUG; Name: Placebo for BMS-986165; Assigned to Arm(s): Placebo
C: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: placebo for ustekinumab | Arm Label: Ustekinumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: ustekinumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for ustekinumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Ustekinumab (Part A) | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Ustekinumab (Part A) | Intervention Type: DRUG; Name: placebo for ustekinumab; Assigned to Arm(s): Placebo (Part A), Risankizumab (Part A)
D: Arm Label: Immediate Methotrexate Cessation; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Gradual Reduction of Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab, Drug: Methotrexate | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Gradual Reduction of Methotrexate, Immediate Methotrexate Cessation | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Gradual Reduction of Methotrexate

Answer: C